IntraMed - Artículos - Tratamiento de la hepatitis crónica
Artículo de revisión | 24 ABR 02
Tratamiento de la hepatitis crónica
El tratamiento de la hepatitis B y C ha mejorado notablemente en los últimos años.
Autor: Dres. Paul J Gow y David Mutimer Fuente: Austin and Repatriation Medical Centre, Victoria, Australia y Queen Elizabeth Hospital, Edgbaston, Birmingham, UK BMJ 2001;323:1164-1167
INDICE:  1. Desarrollo | 2. Referencias
Referencias

1. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 1999;122:133-8.

2. Cunningham R, Northwood JL, Kelly CD, Boxall EH, Andrews NJ. Routine antenatal screening for hepatitis B using pooled sera: validation and review of 10 years experience. J Clin Pathol 1998;51:392-5.

3. Lai CL, Chien RN, Leung NW, Chang TI, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.

4. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30:770-4.

5. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.

6. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl  2000;6:715-20.

7. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.

8. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-15.

9. Perillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.

10. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.

11. Mutimer D, Dowling D, Cane P, Rateliffe D, Tang H, O'Donnell K, et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir Ther 2000;5:273-7.

12. Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster GR. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000;47:277-80.

13. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.

14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.

15. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2000;33:433-8.

16. Poynard T, McHutchison J, Davis GL, Esteban Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.

17. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9.

18. Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, et al. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. J Epidemiol 2000;10:234-40.

Comentarios

Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2014